---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-065497"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2026-10-09T13:02:20+00:00"
generated_at: "2026-10-12T15:16:11.244451+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharmaceuticals CCO Samantha Pearce to retire by June 30, 2027; successor search launched

## Summary
- Executive Vice President and Chief Commercial Officer Samantha Pearce notified Jazz on Oct 6, 2026 of her intent to retire.
- Retirement takes effect upon the earlier of the selection and appointment of her successor or June 30, 2027.
- Jazz plans a formal search for a new Chief Commercial Officer, considering both internal and external candidates.
- No successor has been named; Pearce continues as CCO during the transition.

## SEC filing metadata
- accession: 0001628280-26-065497
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2026-10-09T13:02:20+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000162828026065497/0001628280-26-065497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000162828026065497/jazz-20261006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-065497
- JSON: https://secwatch.observer/filing/0001628280-26-065497.json
- Plain text: https://secwatch.observer/filing/0001628280-26-065497.txt

## Key facts
- Executive change
  Samantha Pearce departed as Executive Vice President, Chief Commercial Officer at Jazz Pharmaceuticals plc.
  - Action: retire
  - Role: Executive Vice President, Chief Commercial Officer
  source text: On October 6, 2026, Samantha Pearce, Executive Vice President, Chief Commercial Officer of Jazz Pharmaceuticals plc (the “Company” ), notified the Company of her intent to retire from her role as Chief Commercial Officer upon the earlier of the selection and appointment of her successor or by June 30, 2027.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000162828026065497/0001628280-26-065497-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.